Drug Target for Cancer: NF-κB

Drug Targets for Cancer: NF-κB and Cancer

The transcription factor NF-κB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-κB is required for the coordination of physiologic immune responses. However, constitutive NF-κB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-κB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either upstream or downstream of the central IκB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis.In recent years it is becoming clear that aberrant deregulated NF-κB activation is a hallmark of several lymphoid malignancies and is directly linked to advanced disease. Several lymphoma types depend on NF-κB activity for cell cycling and survival, indicating that an inhibition of this pathway could be a therapeutic option.

Drug Targets for Cancer: NF-κB related Products

Other vital drug targets for cancer like NF-κB:

Drug Targets for Cancer: NF-κB Related Reference

Jost P J, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications[J]. Blood, 2007, 109(7): 2700-2707.

Drug Targets for Cancer: NF-κB Related Information